Format
Sort by

Send to

Choose Destination

Search results

Items: 18

1.

The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival.

Kilvaer TK, Paulsen EE, Khanehkenari MR, Al-Saad S, Johansen RM, Al-Shibli K, Bremnes RM, Busund LT, Donnem T.

Br J Cancer. 2016 May 10;114(10):1145-51. doi: 10.1038/bjc.2016.92. Epub 2016 Apr 7.

PMID:
27167450
2.

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM.

Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. Review.

PMID:
26578726
3.

Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer--A Structured Review with Meta-Analysis.

Kilvaer TK, Paulsen EE, Hald SM, Wilsgaard T, Bremnes RM, Busund LT, Donnem T.

PLoS One. 2015 Aug 25;10(8):e0132481. doi: 10.1371/journal.pone.0132481. eCollection 2015. Review.

4.

Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.

Kilvaer TK, Khanehkenari MR, Hellevik T, Al-Saad S, Paulsen EE, Bremnes RM, Busund LT, Donnem T, Martinez IZ.

PLoS One. 2015 Aug 7;10(8):e0134965. doi: 10.1371/journal.pone.0134965. eCollection 2015.

5.

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2015 May 29;15:441. doi: 10.1186/s12885-015-1446-z.

6.

Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT.

Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13.

7.

The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund LT, Donnem T.

BMC Clin Pathol. 2014 Jan 20;14(1):5. doi: 10.1186/1472-6890-14-5.

8.

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

BMC Clin Pathol. 2013 Mar 15;13:9. doi: 10.1186/1472-6890-13-9.

9.

Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

PLoS One. 2012;7(10):e47068. doi: 10.1371/journal.pone.0047068. Epub 2012 Oct 5.

10.

Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

BMC Clin Pathol. 2012 May 3;12:7. doi: 10.1186/1472-6890-12-7.

11.

Prognostic impacts of hypoxic markers in soft tissue sarcoma.

Smeland E, Kilvaer TK, Sorbye S, Valkov A, Andersen S, Bremnes RM, Busund LT, Donnem T.

Sarcoma. 2012;2012:541650. doi: 10.1155/2012/541650. Epub 2012 Feb 20.

12.

Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

BMC Clin Pathol. 2012 Feb 29;12:5. doi: 10.1186/1472-6890-12-5.

13.

The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas.

Valkov A, Kilvaer TK, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT.

J Transl Med. 2011 Nov 22;9:200. doi: 10.1186/1479-5876-9-200.

14.

Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients.

Kilvaer TK, Valkov A, Sorbye SW, Smeland E, Bremnes RM, Busund LT, Donnem T.

J Transl Med. 2011 Jul 6;9:104. doi: 10.1186/1479-5876-9-104.

15.

The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas.

Valkov A, Sorbye SW, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Busund LT.

PLoS One. 2011 Mar 3;6(3):e17507. doi: 10.1371/journal.pone.0017507.

16.

Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival.

Kilvaer TK, Valkov A, Sorbye SW, Donnem T, Smeland E, Bremnes RM, Busund LT.

Sarcoma. 2010;2010:751304. doi: 10.1155/2010/751304. Epub 2011 Jan 23.

17.

Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas.

Valkov A, Sorbye S, Kilvaer TK, Donnem T, Smeland E, Bremnes RM, Busund LT.

Int J Oncol. 2011 Apr;38(4):1031-40. doi: 10.3892/ijo.2011.920. Epub 2011 Jan 24.

PMID:
21271213
18.

Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis.

Kilvaer TK, Valkov A, Sorbye S, Smeland E, Bremnes RM, Busund LT, Donnem T.

PLoS One. 2010 Dec 14;5(12):e15368. doi: 10.1371/journal.pone.0015368.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk